Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 9:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 7,881 matching trials from the live ClinicalTrials.gov search.
Conditions
Neuroblastoma
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 96 more
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
524
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 354 more
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Interventions
Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Tucson, Arizona • Daly City, California • San Diego, California + 33 more
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Conditions
Pancreatitis, Chronic; Diabetes; Transplant
Interventions
etanercept, Alpha 1-Antitrypsin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Urothelial Cancer
Interventions
Erdafitinib, Midazolam, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
25
States / cities
Sedona, Arizona • Los Angeles, California • Orange, California + 22 more
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions
Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
429
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more
Not yet recruiting Not applicable Interventional

Focused Ultrasound Neuromodulation for Chronic Pain

NCT07910396
Conditions
Chronic Pain, Sickle Cell Disease, Chronic Pelvic Pain Syndrome
Interventions
Focused PCM-Guided CMN LIFU, Unfocused Control LIFU
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Hemophilia A
Interventions
Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years and older · Male only
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Conditions
Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
1 Month to 16 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Hartford, Connecticut • Washington D.C., District of Columbia + 21 more
Conditions
Obesity & Overweight
Interventions
Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet, Placebo liquid emulsion formulation
Drug
Lead sponsor
Gila Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
180 Days to 22 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
108
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 85 more
Conditions
Migraine Disorders
Interventions
ALD403 (Eptinezumab), Placebo
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
Completed No phase listed Observational

Ragweed Observational Study

NCT01398137
Conditions
Ragweed Allergy
Interventions
Not listed
Lead sponsor
Circassia Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
Owensboro, Kentucky • Minneapolis, Minnesota • Plymouth, Minnesota + 7 more
Completed Phase 2 Interventional Results available

Lactoferrin Treatment in HIV Patients

NCT01830595
Conditions
HIV Infection
Interventions
Recombinant Lactoferrin, Placebo
Drug
Lead sponsor
Jason Baker
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Aortic Aneurysm, Abdominal
Interventions
GORE® EXCLUDER® Conformable AAA Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
21 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 45 more
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
NXL103, Linezolid
Drug
Lead sponsor
Novexel Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Chula Vista, California • Fountain Valley, California • La Mesa, California + 7 more
Conditions
Acute Coronary Syndrome
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
88
States / cities
Jonesboro, Arkansas • Bakersfield, California • Fresno, California + 75 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Not listed No phase listed Observational

GLOBAL Clinical Study

NCT01738828
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Global Genomics Group, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Roseville, California + 22 more
Completed Phase 2Phase 3 Interventional Results available

Semaglutide in CFRD

NCT05788965
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Semaglutide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Compass Course
Other
Lead sponsor
Mary Radomski
Other
Eligibility
25 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism

NCT02999399
Conditions
Smoking
Interventions
Brussel Sprouts, Deuterated Phenanthrene
Other · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota